Marketing authorisations Granted in 2026.
Similar Posts
Side effects from drug interactions to be predicted by AI before reaching patients
The MHRA leads three new government-backed projects using AI-driven approaches to make medicines safer and bring treatments to patients more quickly.
Guidance: Updates to CIR 520/2012 – Information for UK Marketing Authorisation Holders
This guidance clarifies the expectations on the application of the further pharmacovigilance provisions set out within the updated CIR 520/2012 for UK authorised products.
Guidance: GLP-1 medicines for weight loss and diabetes: what you need to know
Guidance on the safe and effective use of GLP-1 medicines for weight loss and diabetes.
Class 2 Medicines Recall: ChloraPrep 1mL Clear Sterile Solution/Applicator, Becton Dickinson UK Ltd, EL(25)A/36
Becton Dickinson UK Ltd has informed the MHRA that some units exhibit an open seal on the packaging of the applicator. This is linked to the Class 2 Medicines Notification EL(25)A/22. This defect could increase the risk of the applicator device being contaminated with pathogens.
Guidance: Medicines that you cannot export from the UK or hoard
Sets out medicines that cannot be exported from the UK or hoarded because they are needed for UK patients.
Guidance: Route B substantial modification pilot
Clinical trials Route B substantial modifications pilot starts on 1 October 2025. Prepare for the implementation of new regulations from 28 April 2026.